AMX0035
Amyotrophic Lateral Sclerosis (ALS)
Key Facts
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is dedicated to creating new possibilities for people living with debilitating neurodegenerative diseases by targeting key cellular pathways of neurodegeneration. The company achieved a landmark success with the U.S. FDA approval of RELYVRIO (AMX0035) for ALS in September 2022, transitioning from a clinical-stage to a commercial-stage entity. Its strategy involves maximizing the global potential of RELYVRIO while advancing its next-generation candidate, AMX0114, and exploring the application of its dual-mechanism platform in other diseases like Wolfram syndrome and progressive supranuclear palsy (PSP). Amylyx faces the critical challenge of commercial execution and confirming the clinical benefit of its lead asset in an ongoing confirmatory trial.
View full company profileAbout Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is dedicated to creating new possibilities for people living with debilitating neurodegenerative diseases by targeting key cellular pathways of neurodegeneration. The company achieved a landmark success with the U.S. FDA approval of RELYVRIO (AMX0035) for ALS in September 2022, transitioning from a clinical-stage to a commercial-stage entity. Its strategy involves maximizing the global potential of RELYVRIO while advancing its next-generation candidate, AMX0114, and exploring the application of its dual-mechanism platform in other diseases like Wolfram syndrome and progressive supranuclear palsy (PSP). Amylyx faces the critical challenge of commercial execution and confirming the clinical benefit of its lead asset in an ongoing confirmatory trial.
View full company profileAbout Amylyx Pharmaceuticals
Amylyx Pharmaceuticals is dedicated to creating new possibilities for people living with debilitating neurodegenerative diseases by targeting key cellular pathways of neurodegeneration. The company achieved a landmark success with the U.S. FDA approval of RELYVRIO (AMX0035) for ALS in September 2022, transitioning from a clinical-stage to a commercial-stage entity. Its strategy involves maximizing the global potential of RELYVRIO while advancing its next-generation candidate, AMX0114, and exploring the application of its dual-mechanism platform in other diseases like Wolfram syndrome and progressive supranuclear palsy (PSP). Amylyx faces the critical challenge of commercial execution and confirming the clinical benefit of its lead asset in an ongoing confirmatory trial.
View full company profileTherapeutic Areas
Other Amyotrophic Lateral Sclerosis (ALS) Drugs
| Drug | Company | Phase |
|---|---|---|
| Utreloxastat (PTC857) | PTC Therapeutics | Phase 2 |
| SAR443820/DNL788 | Denali Therapeutics | Phase 2 |
| Pegcetacoplan | Apellis Pharmaceuticals | Phase 2 |
| RELYVRIO/ALBRIOZA (AMX0035) | Amylyx Pharmaceuticals | Approved/Commercial |
| AMX0114 | Amylyx Pharmaceuticals | Phase 1 |
| Taldefgrobep alfa | Biohaven | Phase 2/3 |
| AMT-162 | uniQure | Preclinical |
| AAV-UPF1 | MeiraGTx | Preclinical |
| Tegoprubart | Eledon Pharmaceuticals | Phase 2 |
| Intranasal Foralumab | Tiziana Life Sciences | Phase 2 |
| TDP-43 Program | Korro Bio | Discovery |
| COYA 302 | Coya Therapeutics | Phase 2 |